Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Higher serological responses and increased vaccine effectiveness demonstrate the value of extended vaccine schedules in combatting COVID-19 in England

Gayatri Amirthalingam, Jamie Lopez Bernal, Nick J Andrews, Heather Whitaker, Charlotte Gower, Julia Stowe, Elise Tessier, Vani Subbarao, Georgina Ireland, Frances Baawuah, Ezra Linley, Lenesha Warrener, Michelle O’Brien, Corinne Whillock, Paul Moss, Shamez N Ladhani, Kevin E Brown, Mary E Ramsay
doi: https://doi.org/10.1101/2021.07.26.21261140
Gayatri Amirthalingam
1Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gayatri.amirthalingam{at}phe.gov.uk
Jamie Lopez Bernal
1Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nick J Andrews
2Statistics, Modelling and Economics Department, National Infection Service, Public Health England, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather Whitaker
2Statistics, Modelling and Economics Department, National Infection Service, Public Health England, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charlotte Gower
1Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Stowe
1Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elise Tessier
1Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vani Subbarao
1Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georgina Ireland
1Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frances Baawuah
1Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom
3Brondesbury Medical Centre, Kilburn, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ezra Linley
4Sero-Epidemiolgy Unit, National Infection Service, Public Health England, Manchester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lenesha Warrener
5Virus Reference Department, National Infection Service, Public Health England, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle O’Brien
3Brondesbury Medical Centre, Kilburn, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Corinne Whillock
1Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Moss
6Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shamez N Ladhani
1Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom
7Paediatric Infectious Diseases Research Group, St. George’s University of London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin E Brown
1Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary E Ramsay
1Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

Abstract

Introduction In January 2021, the UK decided to prioritise the delivery of the first dose of BNT162b2 (Pfizer/BioNTech) and AZD1222 (AstraZeneca) vaccines by extending the interval until the second dose up to 12 weeks.

Methods Serological responses were compared after BNT162b2 and AZD1222 vaccination with varying intervals in uninfected and previously-infected adults aged 50-89 years. These findings are evaluated against real-world national vaccine effectiveness (VE) estimates against COVID-19 in England.

Results We recruited 750 participants aged 50-89 years, including 126 (16.8%) with evidence of previous infection; 421 received BNT162b2 and 329 and AZD1222. For both vaccines, over 95% had seroconverted 35-55 days after dose one, and 100% seroconverted 7+ days after dose 2. Following a 65-84 day interval between two doses, geometric mean titres (GMTs) at 14-34 days were 6-fold higher for BNT162b2 (6703; 95%CI, 5887-7633) than AZD1222 (1093; 806-1483), which in turn were higher than those receiving BNT162b2 19-29 days apart (694; 540 - 893). For both vaccines, VE was higher across all age-groups from 14 days after dose two compared to one dose, but the magnitude varied with interval between doses. Higher two-dose VE was observed with >6 week intervals between BNT162b2 doses compared to the authorised 3-week schedule, including ≥80 year-olds.

Conclusion Our findings support the UK approach of prioritising the first dose of COVID-19 vaccines, with evidence of higher protection following extended schedules. Given global vaccine constraints, these results are relevant to policymakers, especially with highly transmissible variants and rising incidence in many countries.

Funding Public Health England

Competing Interest Statement

MER reports that the Immunisation and Countermeasures Division (PHE) has provided vaccine manufacturers with post-marketing surveillance reports on pneumococcal and meningococcal infection, which the companies are required to submit to the UK licensing authority in compliance with their risk management strategy. A cost-recovery charge is made for these reports. EL report that the PHE Vaccine Evaluation Unit does contract research on behalf of GlaxoSmithKline, Sanofi, and Pfizer, which is outside the submitted work.

Funding Statement

This surveillance was funded by Public Health England.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This surveillance was funded by Public Health England. The CONSENSUS study/audit was approved by PHEs R&D Research Ethics and Governance Group. No NR0253

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted July 28, 2021.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Higher serological responses and increased vaccine effectiveness demonstrate the value of extended vaccine schedules in combatting COVID-19 in England
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Higher serological responses and increased vaccine effectiveness demonstrate the value of extended vaccine schedules in combatting COVID-19 in England
Gayatri Amirthalingam, Jamie Lopez Bernal, Nick J Andrews, Heather Whitaker, Charlotte Gower, Julia Stowe, Elise Tessier, Vani Subbarao, Georgina Ireland, Frances Baawuah, Ezra Linley, Lenesha Warrener, Michelle O’Brien, Corinne Whillock, Paul Moss, Shamez N Ladhani, Kevin E Brown, Mary E Ramsay
medRxiv 2021.07.26.21261140; doi: https://doi.org/10.1101/2021.07.26.21261140
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Higher serological responses and increased vaccine effectiveness demonstrate the value of extended vaccine schedules in combatting COVID-19 in England
Gayatri Amirthalingam, Jamie Lopez Bernal, Nick J Andrews, Heather Whitaker, Charlotte Gower, Julia Stowe, Elise Tessier, Vani Subbarao, Georgina Ireland, Frances Baawuah, Ezra Linley, Lenesha Warrener, Michelle O’Brien, Corinne Whillock, Paul Moss, Shamez N Ladhani, Kevin E Brown, Mary E Ramsay
medRxiv 2021.07.26.21261140; doi: https://doi.org/10.1101/2021.07.26.21261140

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (434)
  • Allergy and Immunology (760)
  • Anesthesia (222)
  • Cardiovascular Medicine (3316)
  • Dentistry and Oral Medicine (366)
  • Dermatology (282)
  • Emergency Medicine (480)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1175)
  • Epidemiology (13402)
  • Forensic Medicine (19)
  • Gastroenterology (900)
  • Genetic and Genomic Medicine (5181)
  • Geriatric Medicine (483)
  • Health Economics (786)
  • Health Informatics (3286)
  • Health Policy (1146)
  • Health Systems and Quality Improvement (1199)
  • Hematology (432)
  • HIV/AIDS (1024)
  • Infectious Diseases (except HIV/AIDS) (14657)
  • Intensive Care and Critical Care Medicine (917)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (526)
  • Neurology (4957)
  • Nursing (263)
  • Nutrition (735)
  • Obstetrics and Gynecology (889)
  • Occupational and Environmental Health (797)
  • Oncology (2531)
  • Ophthalmology (730)
  • Orthopedics (284)
  • Otolaryngology (348)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (547)
  • Pediatrics (1308)
  • Pharmacology and Therapeutics (552)
  • Primary Care Research (559)
  • Psychiatry and Clinical Psychology (4224)
  • Public and Global Health (7526)
  • Radiology and Imaging (1717)
  • Rehabilitation Medicine and Physical Therapy (1022)
  • Respiratory Medicine (982)
  • Rheumatology (480)
  • Sexual and Reproductive Health (500)
  • Sports Medicine (425)
  • Surgery (551)
  • Toxicology (73)
  • Transplantation (237)
  • Urology (206)